Nakauchi Y, Kumon Y, Yamasaki H, Tahara K, Kurisaka M, Hashimoto K
Second Department of Internal Medicine, Kochi Medical School, Japan.
Endocr J. 1995 Jun;42(3):385-9. doi: 10.1507/endocrj.42.385.
We used octreotide to treat a woman with acromegaly and observed pituitary adenoma shrinkage after 5 months. Diffuse scalp hair loss occurred after 5 months, resulting in the discontinuation of treatment. After the cessation of octreotide, the hair loss stopped and hair growth resumed. Since bromocriptine did not effectively decrease the GH level of the patient, we decided to perform transsphenoidal surgery. After resection of the pituitary adenoma, her GH and IGF-1 levels were normalized. Although octreotide-induced scalp hair loss has not been well recognized, we should pay more attention to this side effect.
我们使用奥曲肽治疗一名肢端肥大症女性患者，5个月后观察到垂体腺瘤缩小。5个月后出现弥漫性头皮脱发，导致治疗中断。停用奥曲肽后，脱发停止，头发重新生长。由于溴隐亭未能有效降低该患者的生长激素水平，我们决定进行经蝶窦手术。切除垂体腺瘤后，她的生长激素和胰岛素样生长因子-1水平恢复正常。尽管奥曲肽引起的头皮脱发尚未得到充分认识，但我们应更多地关注这一副作用。
